During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

Chimeric antigen receptor T cell therapy is a revolutionary approach that is a new pillar in the treatment of cancer. CAR T cell therapy has produced remarkable results in hematological malignancies; ...

This is best exemplified by chimeric antigen receptor (CAR) T-cells. Since first being tested in a patient nearly 15 years ago, six CAR T-cell products have been approved by the US Food and Drug ...

Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that ...

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Colon Cancer. According to GlobalData, Phase II drugs for Colon Cancer have an 11% phase transition ...

T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response. The ...

For more information, please visit www.autolus.com About obe-cel (AUTO1) Obecabtagene autoleucel (obe-cel) is a B-lymphocyte antigen CD19 (CD19) chimeric antigen receptor (CAR) T cell investigational ...

1 Department of Hematology, The Forth Affiliated Hospital of China Medical University, Shenyang, China 2 Department of Breast Surgery, The First Affiliated Hospital of China Medical University, ...

“I am honored to have been named a K12 scholar,” says McNerney. “To me, this represents Northwestern’s commitment to my ...